FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308134474> ?p ?o ?g. }

• W4308134474 endingPage "A548" @default.
• W4308134474 startingPage "A547" @default.
• W4308134474 abstract "Abstract Background Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States who have previously responded to injectable somatostatin receptor ligands (iSRLs, octreotide or lanreotide). In previous phase 3 studies, the safety of OOC was shown to be consistent with iSRLs, without dose-dependent adverse reactions. In the double-blind, placebo-controlled period (DPC) of the CHIASMA OPTIMAL trial (NCT03252353), patients were randomized to twice-daily OOC at 40-mg/day, with the option for up-titration to 80-mg/day. In contrast, patients entered the open-label extension (OLE) at a 60-mg/day dose. Objective Examine the safety of 40-mg/day versus 60-mg/day OOC doses. Methods Eligible patients had the option to enroll in the OLE following the core trial. All patients received OOC 60-mg/day upon entering the OLE regardless of prior treatment in the DPC, including patients who received placebo in the DPC. OOC doses were up- or down-titrated based on insulin-like growth factor I (IGF-I) level and/or acromegaly signs or symptoms. The current analysis compared the incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), TEAE-related study drug discontinuation, and acromegaly-related TEAEs (defined as new or worsening signs or symptoms of acromegaly). Results Twenty-eight patients randomized to OOC in the DPC (40-mg/day dose) and 19 who were originally randomized to placebo and continued into the OLE (60-mg/day dose) were included in the analysis. Biochemical control was similar in both groups as demonstrated by mean IGF-I levels over the respective periods. Ninety-six percent of patients on 40-mg/day and 57.9% on 60-mg/day experienced ≥1 TEAEs. Two patients on 60-mg/day reported a total of 2 SAEs, both deemed unrelated to study drug. Two patients on 40-mg/day experienced TEAEs leading to study drug discontinuation (headache and gastrointestinal symptoms). The incidence of acromegaly-related TEAEs was generally lower in those on 60-mg/day versus 40-mg/day. Conclusions This is the first analysis exploring differences in OOC doses. The nature and incidence of TEAEs occurring with an OOC dose of 60-mg/day versus 40-mg/day were similar, though this analysis was limited by differences in TEAE reporting across sequential phases of a lengthy trial. A trend was observed for decreased incidence of acromegaly-related TEAEs with the 60-mg/day dose. This finding is in line with previous analyses showing no dose-related TEAEs with OOC. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m." @default.
• W4308134474 created "2022-11-08" @default.
• W4308134474 creator A5003838671 @default.
• W4308134474 creator A5007146249 @default.
• W4308134474 creator A5013244431 @default.
• W4308134474 creator A5022118831 @default.
• W4308134474 creator A5024070567 @default.
• W4308134474 creator A5042807722 @default.
• W4308134474 creator A5045002153 @default.
• W4308134474 creator A5048100872 @default.
• W4308134474 creator A5049091175 @default.
• W4308134474 creator A5060451560 @default.
• W4308134474 creator A5065697805 @default.
• W4308134474 creator A5066985276 @default.
• W4308134474 creator A5091436678 @default.
• W4308134474 date "2022-11-01" @default.
• W4308134474 modified "2023-09-25" @default.
• W4308134474 title "PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial" @default.
• W4308134474 doi "https://doi.org/10.1210/jendso/bvac150.1138" @default.
• W4308134474 hasPublicationYear "2022" @default.
• W4308134474 type Work @default.
• W4308134474 citedByCount "0" @default.
• W4308134474 crossrefType "journal-article" @default.
• W4308134474 hasAuthorship W4308134474A5003838671 @default.
• W4308134474 hasAuthorship W4308134474A5007146249 @default.
• W4308134474 hasAuthorship W4308134474A5013244431 @default.
• W4308134474 hasAuthorship W4308134474A5022118831 @default.
• W4308134474 hasAuthorship W4308134474A5024070567 @default.
• W4308134474 hasAuthorship W4308134474A5042807722 @default.
• W4308134474 hasAuthorship W4308134474A5045002153 @default.
• W4308134474 hasAuthorship W4308134474A5048100872 @default.
• W4308134474 hasAuthorship W4308134474A5049091175 @default.
• W4308134474 hasAuthorship W4308134474A5060451560 @default.
• W4308134474 hasAuthorship W4308134474A5065697805 @default.
• W4308134474 hasAuthorship W4308134474A5066985276 @default.
• W4308134474 hasAuthorship W4308134474A5091436678 @default.
• W4308134474 hasBestOaLocation W43081344741 @default.
• W4308134474 hasConcept C126322002 @default.
• W4308134474 hasConcept C142724271 @default.
• W4308134474 hasConcept C168563851 @default.
• W4308134474 hasConcept C197934379 @default.
• W4308134474 hasConcept C204787440 @default.
• W4308134474 hasConcept C27081682 @default.
• W4308134474 hasConcept C2776297358 @default.
• W4308134474 hasConcept C2777433750 @default.
• W4308134474 hasConcept C2778715236 @default.
• W4308134474 hasConcept C2779609023 @default.
• W4308134474 hasConcept C2781025020 @default.
• W4308134474 hasConcept C2984496839 @default.
• W4308134474 hasConcept C71315377 @default.
• W4308134474 hasConcept C71924100 @default.
• W4308134474 hasConceptScore W4308134474C126322002 @default.
• W4308134474 hasConceptScore W4308134474C142724271 @default.
• W4308134474 hasConceptScore W4308134474C168563851 @default.
• W4308134474 hasConceptScore W4308134474C197934379 @default.
• W4308134474 hasConceptScore W4308134474C204787440 @default.
• W4308134474 hasConceptScore W4308134474C27081682 @default.
• W4308134474 hasConceptScore W4308134474C2776297358 @default.
• W4308134474 hasConceptScore W4308134474C2777433750 @default.
• W4308134474 hasConceptScore W4308134474C2778715236 @default.
• W4308134474 hasConceptScore W4308134474C2779609023 @default.
• W4308134474 hasConceptScore W4308134474C2781025020 @default.
• W4308134474 hasConceptScore W4308134474C2984496839 @default.
• W4308134474 hasConceptScore W4308134474C71315377 @default.
• W4308134474 hasConceptScore W4308134474C71924100 @default.
• W4308134474 hasIssue "Supplement_1" @default.
• W4308134474 hasLocation W43081344741 @default.
• W4308134474 hasLocation W43081344742 @default.
• W4308134474 hasOpenAccess W4308134474 @default.
• W4308134474 hasPrimaryLocation W43081344741 @default.
• W4308134474 hasRelatedWork W1573871019 @default.
• W4308134474 hasRelatedWork W2004517907 @default.
• W4308134474 hasRelatedWork W2040810181 @default.
• W4308134474 hasRelatedWork W2075577428 @default.
• W4308134474 hasRelatedWork W2082305347 @default.
• W4308134474 hasRelatedWork W2082603372 @default.
• W4308134474 hasRelatedWork W2524546317 @default.
• W4308134474 hasRelatedWork W2550912936 @default.
• W4308134474 hasRelatedWork W2600584706 @default.
• W4308134474 hasRelatedWork W4308134474 @default.
• W4308134474 hasVolume "6" @default.
• W4308134474 isParatext "false" @default.
• W4308134474 isRetracted "false" @default.
• W4308134474 workType "article" @default.